Infectious Disease Diagnostics Testing Global Market Observe Highest Growth of $58.84 Billion with an Excellent CAGR of 10.2% by 2028 | Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Grifols S.A., Hologic Inc.

The Business Research Company recently released a comprehensive report on the Global Infectious Disease Diagnostics Testing Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15831&type=smp

According to The Business Research Company's, The infectious disease diagnostics testing market size has grown strongly in recent years. It will grow from $35.09 billion in 2023 to $38.52 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rising disease outbreaks such as SARS, Ebola, and Zika, growing awareness among healthcare professionals and the general public about the importance of early detection and prevention of infectious diseases, rise in government-funded programs for disease surveillance, control, and prevention, increasing global travel and trade have facilitated the spread of infectious diseases, and increased healthcare spending, particularly in emerging economies.

The infectious disease diagnostics testing market size is expected to see rapid growth in the next few years. It will grow to $58.84 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the continuous emergence of novel pathogens, such as new strains of influenza or coronaviruses, the shift towards personalized medicine and targeted therapies, increasing demand for rapid and on-site testing solutions, Growing emphasis on epidemiological surveillance and early detection systems, and increased research and developments activities focused on developing novel diagnostic technologies and biomarkers. Major trends in the forecast period include miniaturization and portability of diagnostic devices, adoption of multiplex assays capable of detecting multiple pathogens simultaneously, integration of digital health solutions, such as mobile apps and telemedicine platforms, adoption of next-generation sequencing (NGS) technologies in infectious disease diagnostics, advancements in biosensor technologies for rapid and sensitive detection of infectious agents, and integration of AI and machine learning algorithms into diagnostic platforms

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Market Drivers and Trends:

The rising prevalence of epilepsy is expected to propel the growth of the epileptic seizures treatment market going forward. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. These seizures are the result of abnormal electrical activity in the brain, which can cause a variety of symptoms, including convulsions, loss of consciousness, and disturbances in sensory perception or behavior. The rising prevalence of epilepsy can be attributed to various factors, such as the higher survival rates of individuals with brain injuries or strokes and a growing aging population. Effective epileptic seizure treatments, primarily through the use of AEDs, can significantly reduce the frequency and severity of seizures in patients. These medications help maintain seizure-free periods by stabilizing neuronal activity in the brain, which is critical for patients' daily functioning and overall well-being. For instance, in February 2024, according to the World Health Organization, a Switzerland-based public health agency of the United Nations, approximately 50 million people in the world were suffering from epilepsy, making it one of the most prevalent neurological conditions worldwide. Every year, about 5 million people are diagnosed with epilepsy. Therefore, the rising prevalence of epilepsy is driving the growth of the epileptic seizures treatment market.

Major companies operating in the infectious disease diagnostic testing market are focusing on developing innovative technologies, such as molecular diagnostics platforms, to sustain their position in the market. Molecular diagnostics platforms are sophisticated systems designed to detect and analyze nucleic acids (DNA or RNA) from biological samples for diagnostic purposes. For instance, in May 2022, Becton Dickinson, and Company, a US-based medical technology company, launched BD COR System, a fully automated, high-throughput infectious disease molecular diagnostics platform. This platform integrates and automates the complete molecular laboratory workflow from sample processing to diagnostic results, eliminating the need for manual specimen sorting and freeing up lab technicians for higher-value tasks. The system can process up to 1,700 specimens and deliver results within 24 hours, offering high-throughput capabilities and advanced genotyping for diseases such as HPV and STIs.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Myriad Genetics Inc., Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC, Biodesix Inc., Helix OpCo LLC, Inovio Pharmaceuticals Inc.

Infectious Disease Diagnostics Testing Market 2024 Key Insights:

• The infectious disease diagnostics testing market size is expected to see rapid growth in the next few years. It will grow to $58.84 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%.
• Impact Of Rising Respiratory Infections On The Infectious Disease Diagnostic Testing Market
• Advancements In Molecular Diagnostics Platforms Drive Innovation In The Infectious Disease Diagnostic Testing Market
• North America was the largest region in the infectious disease diagnostics testing market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=15831&type=smp

Contact Us:

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.